Patent · US Active

Elimination of immune responses to viral vectors

US9861661B2 · kind B2 · utility

13Cited by
7References
15Claims
0Family size

Assignees

Inventor

Key dates

Filing dateApr 15, 2015
Grant dateJan 9, 2018
Priority date
Expiry dateApr 15, 2035

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2740/15071
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from a viral vector antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and/or suppression of immune responses to viral vectors and in the manufacture of medicaments therefore.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.